Anti-doping testing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
== Applications == Commercially, homoserine can serve as precursor to the synthesis of isobutanol and 1,4-butanediol. Purified homoserine is used in enzyme structural studies. Also, homoserine has played important roles in studies to elucidate peptide synthesis and synthesis of proteoglycan glycopeptides. Bacterial cell lines can make copious amounts of this amino acid.
=== Alcohol use disorder === Naltrexone has been best studied as a treatment for alcoholism, or alcohol use disorder (AUD). Naltrexone has been shown to decrease the quantity and frequency of alcohol consumption by reducing the release of dopamine, a neurotransmitter associated with the euphoria that often accompanies alcohol use. Studies comparing naltrexone to a placebo have shown a small but statistically significant decrease in relapse likelihood. Its overall benefit has been described as "modest". Acamprosate may be more effective for AUD management overall, while naltrexone may decrease the desire for alcohol to a greater extent. A method pioneered by scientist John David Sinclair (dubbed commercially the "Sinclair Method") in the 1980s advocates "pharmacological extinction" of problem drinking behavior by administering naltrexone alongside controlled alcohol consumption. In effect, he argues that naltrexone-induced opioid antagonism sufficiently disrupts reflexive reward mechanisms inherent in the consumption of alcohol and, given enough repetition, will dissociate positive associations formerly made with the consumption of alcohol. A 2001 review of eight studies of naltrexone treatment in the setting of AUD concluded that, "although all found benefits from naltrexone with the coping therapy, none of them found any significant benefit of naltrexone over placebo when combined with support for abstinence."
In June 2021, Biden took his first trip abroad as president, visiting Belgium, Switzerland, and the United Kingdom. He attended a G7 summit, a NATO summit, and an EU summit, and held one-on-one talks with Russian president Vladimir Putin. In September 2021, Biden announced AUKUS, a defense pact between Australia, the United Kingdom and the United States, to ensure "peace and stability in the Indo-Pacific". In February 2021, the Biden administration announced that the United States was ending its support for the Saudi-led bombing campaign in Yemen and revoked the designation of Yemen's Houthis as terrorists. In early February 2022, Biden ordered the counterterrorism raid in northern Syria that resulted in the death of Abu Ibrahim al-Hashimi al-Qurashi, the second leader of the Islamic State. In late July, Biden approved the drone strike that killed Ayman al-Zawahiri, the second leader of Al-Qaeda, and an integral member in the planning of the September 11 attacks. The 2022 OPEC+ oil production cut caused a diplomatic spat with Saudi Arabia, threatening a longstanding alliance. In August 2024, Biden negotiated and oversaw the 2024 Ankara prisoner exchange, the largest prisoner exchange since the end of the Cold War. It involved the release of 26 people, including journalist Evan Gershkovich and former Marine Paul Whelan. In November 2024, the Biden administration announced that it had helped broker a ceasefire agreement in the Israel–Hezbollah conflict.
=== Civil society === Reactions also came from European civil society organisations. Transparency International described the incident as "the most egregious case" of alleged corruption the European Parliament has ever seen. The founder of the Good Lobby commented that "[w]hatever its final outcome, [the] Qatar 'corruption' scandal has unveiled an inconvenient, and for most Europeans already obvious, truth. Money does buy influence in the EU", and that "[t]he EU Parliament and most of its members have historically resisted stricter integrity rules and [an] effective enforcement system." As news broke of the investigation, the honorary board of the implicated NGO, Fight Impunity, resigned en masse. The board members included high-profile European policymakers including Federica Mogherini (former EU High Representative in the Juncker Commission), Bernard Cazeneuve (formerly Prime Minister of France), Dimitris Avramopoulos (former EU Commissioner for Migration, Home Affairs and Citizenship in the Juncker Commission), Cecilia Wikström (former MEP) and Emma Bonino (former EU Commissioner for Health and Consumer Protection in the Santer Commission). The honorary board has no executive or managerial role, so there is no suspicion or accusations against any member of the board. Visentini originally voluntarily stood down temporarily as president of the International Trade Union Congress but a specially convened Extraordinary Meeting of the General Council voted to suspend him of all of his duties.
Sources: en.wikipedia.org
==== Termination of Peter Rost (2005) ==== Peter Rost was vice president in charge of the endocrinology division at Pharmacia before its acquisition by Pfizer. During that time he raised concerns internally about kickbacks and off-label marketing of Genotropin, Pharmacia's human growth hormone drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. Pfizer won a summary dismissal of the case, with the court ruling that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblower activities.
== Medical uses == Lurasidone is used to treat schizophrenia and bipolar disorder. In bipolar disorder, it has been studied both as a monotherapy and adjunctive treatment to lithium or valproate. The European Medicines Agency approved lurasidone for the treatment of schizophrenia for people aged 13 years and older. Its use in Europe for bipolar disorder is considered off-label. In the United States, it is used to treat schizophrenia for people aged 13 years and older. In July 2013, lurasidone received approval for bipolar I depression. This includes depressive episodes of bipolar disorder age 10 and over as a monotherapy, and in conjunction with lithium or valproate in adults. In June 2020, lurasidone was approved in Japan, eight years after its first approval in the United States. In Japan it is approved for bipolar depression and schizophrenia. Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia. Few available atypical antipsychotics are known to possess antidepressant efficacy in bipolar disorder (with the notable exceptions being cariprazine, quetiapine, olanzapine and possibly asenapine) as a monotherapy. The majority of atypical antipsychotics are known to possess significant antimanic activity, however lurasidone is unusual as it was never studied for acute mania.
lists each of the twenty possible outcomes for an amino acid — it can mutate into one of the 19 other amino acids, or remain unchanged. Since the non-diagonal entries listing the probabilities of each of the 19 mutations are known, and the sum of the probabilities of these twenty outcomes must be 1, this last probability can be calculated by
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.